Access Pharmaceuticals (ACCP.ob) is an emerging pharmaceuticals company with a focus on oncology and diabetes.
Favorite Pages
Photos
2 albumsSee All
Cobalamin Delivery SystemsCreated about 5 months ago
MuGardCreated about 6 months ago
No one has added fan photos.
Access Pharmaceuticals, Inc. Access presenting in London next week, December 3, at the ProActive Investors One2One Forum ... to provide investor presentation and meet investors in one-on-one situations ... see proactiveinvestors.com for details ...
Access Pharmaceuticals, Inc. Go to OneMedPlace.com for a recent interview of Access' CEO ... with senior biotechnology analyst Jonathan Aschoff, Ph.D. from Brean Murray Carret & Co. in New York ... update on MuGard global launch, ProLindac, Thiarabine and the cobalamin oral insulin and oral HGH programs ...
www.onemedplace.com
In August, OneMedPlace reported on MuGard, a preventive treatment for oral mucositis from Access Pharmaceuticals. MuGard is currently being launched in Europe, and is expected to hit the North American ...
Access Pharmaceuticals, Inc. Check out some articles from Mike Havrilla from the biotech blog, MikeHavRx.com ...
www.mikehavrx.com
MikeHavRx.com is your prescription for profits, focusing on emerging small / micro-cap investment opportunities from the healthcare sector and my innovative global stock indexes.
Access Pharmaceuticals, Inc. Access Pharma ($ACCP) is featured in this week's BusinessWeek column "Inside Wall Street," by Gene Marcial ... see link below ... also, there's an interview of Gene Marcial on the linked page, which talks about his three choices for this week.
Access Pharmaceuticals, Inc. Article on Access Pharma's MuGard, an FDA approved treatment for oral mucositis that is commercially launched in Europe ... Access recently announced signing a manufacturing agreement with Accupac, Inc. here in the US for manufacturing. Oral mucositis is a common and very debilitating side effect of radiation and chem...otherapy treatments. See accesspharma.com for additional information ...
breastcancer.about.com
Mucositis, and particularly oral mucositis, is a common side effect of chemotherapy. MuGard is a prescription mouthwash that has been shown to help with mucositis prevention when used before chemotherapy and radiation treatments. ...
See MoreAccess Pharmaceuticals, Inc. Update from BioMedReports.com on Access, from Mike Havrilla ... also on SeekingAlpha.com ... $ACCP
biomedreports.com
On 9/10/09, Access Pharma (OTC: ACCP. OB) announced that its clinical development team recently met with its partners Aosaikang Medicinal Group (ASK) in China and JCOM, Ltd. (JCOM) in Korea, along with key opinion leaders in oncology indications to
Access Pharmaceuticals, Inc. NEW Update by Mike Havrilla of BioMedReports.com on Access Pharmaceuticals, Inc. Access Pharma will present at Rodman & Renshaw's Annual Investment Conference next week, on September 11, at 10:45 am ... that presentation will be video webcasted, together with the slides as well.
biomedreports.com
Access Pharma (ACCP.ob) CEO Interview: Updates and Outlook. Jeffrey B. Davis provides an update and the outlook for near-term catalysts for Access Pharma.
Access Pharmaceuticals, Inc. Access Pharma has a new Twitter account ... Access_Pharma ... please become a follower, and spread the word. Check back frequently for updates on Access Pharma's programs.
www.twitter.com
Access Pharmaceuticals (ACCP.OB) is an emerging pharmaceuticals company with a focus on oncology and diabetes.
Access Pharmaceuticals, Inc. Knowcancer.com is a online community dedicated to connecting, educating and empowering all people affected by the many forms of cancer. They have recently wrote a blog about MuGard.
www.knowcancer.com
MuGard is a viscous, mucoadhesive rinse which provides a protective coating to the oral mucosa. Made by Access Pharma for cancer patients dealing with mucositis.
Access Pharmaceuticals, Inc. We issued the following press release today:
pitch.pe
Enrolling Ovarian Cancer Patients in France; Finalizing Clinical Trial Programs with Partners in China and Korea
Access Pharmaceuticals, Inc. Griffin Securities issues an update with a new 12-month target of $11.00 for ACCP shares.
pitch.pe
ACCP COMMENCE MUGARD PRE-MARKETING ACTIVITIES WHILE SEEKING BIG PHARMA PARTNERSHIPS
Access Pharmaceuticals, Inc. Check out link to Mike Havrilla's pieces (with link to full report) on biomedreports.com ... he's also posted on SeekingAlpha. Mike has great grasp on biotechnology sector, and a large following. Analysis is very solid; overview and insights on Access Pharma are solid. Mike was recently quoted in BusinessWeek article on biotech sector.
Access Pharma Report: MuGard Sales, Pipeline Offer Big Upside Potential - Mike Havrilla -- Seeking A
seekingalpha.com
Access Pharma (OTC: ACCP) (ACCP.OB) is an emerging bio-pharmaceutical company which is focusing on the development of a late-stage, diversified oncology pipeline in addition to a treatment called MuGard ...
Access Pharmaceuticals, Inc. "...Normally, roughly 100% of patients undergoing radiation treatment for head and neck cancer experience some level of oral mucositis... all or substantially all of the patients using MuGard, and using it prophylactically, are not getting oral mucositis..."
pitch.pe
Mugard shown effective in preventing oral mucositis in head and neck cancer patients undergoing radiation
Access Pharmaceuticals, Inc. New article on oral mucositis, that mentions MuGard ... check it out below, and at BlissTree dot com ...
www.blisstree.com
Mucositis, the inflammation of the mucosal cells in your mouth become red, inflammed, and very painful. It can be caused by several things, such a:
